GHK-Cu — the copper peptide found in human plasma at twenty
8 min read · Uplevel editorial
In 1973, a biochemist named Loren Pickart was working on a specific and narrow question: why do liver cells from old rats lose the ability to synthesize proteins the way young liver cells do. He wasn't looking for an anti-aging compound. He was doing the kind of foundational molecular biology that rarely makes headlines — comparing albumin synthesis rates across tissue samples, looking for a signal that explained the difference in behavior between aged and young cells. What he found was a peptide in human plasma, tiny and overlooked, that could restore the protein-synthesis activity of old liver cells to something close to youthful function. He called it GHK. The copper-binding property came later, after he characterized the full molecule: glycyl-L-histidyl-L-lysine. Three amino acids, one copper ion, and a set of biological effects that took the better part of four decades to partially map.
That discovery went unnoticed for a remarkably long time. This is worth sitting with: a compound found in human blood, shown in the early 1970s to have measurable biological effects on aging tissue, languished in relative obscurity while the pharmaceutical industry pursued other directions. The story of GHK-Cu is, in part, a story about how the most important biological signals sometimes hide in the most obvious places.
Pickart was completing his doctoral work at the University of California, with research conducted at institutions including Stanford and UC Davis. The plasma fraction he identified wasn't exotic — it was present in everyone's blood, at concentrations that appeared to correlate meaningfully with age. In young adults around twenty, plasma concentrations measured roughly 200 nanograms per milliliter. By age sixty, that number had dropped to around 80 nanograms per milliliter. This wasn't a trace compound that fluctuated with illness or stress. It was a reliable age-associated marker, present in abundance when biological systems were working at their best and declining in concert with the biological processes we associate with aging. Whether this decline is a cause of aging, a consequence of it, or both is still being investigated. But the correlation was striking enough in 1973 to warrant attention, and it remained striking enough to anchor decades of subsequent research.
The early work focused on what GHK did in tissue samples — the cellular biology before any clinical implication had been considered. Pickart observed that the compound appeared to influence gene expression in aged cells in ways that moved them back toward patterns typical of younger cells. This is not the same as saying it reversed aging. But it pointed at a mechanism that was far more interesting than a simple antioxidant or anti-inflammatory effect. Something about this small tripeptide seemed to interface with how cells read their own genetic instructions. Unpacking what that meant would take decades.
The copper binding was the next piece. GHK alone has biological activity. GHK complexed with copper(II) ions — the form now typically written as GHK-Cu — has considerably more. Copper is not a passive component here. It's a cofactor in critical enzymatic reactions throughout the body, including lysyl oxidase, which cross-links collagen and elastin to give them structural strength, and superoxide dismutase, one of the body's primary antioxidant enzymes. The affinity with which GHK binds copper is extraordinary — higher than most other known copper-binding peptides of comparable size. This binding is thought to deliver copper to cells in a form that's bioavailable but not toxic, which matters because free copper in biological systems is oxidatively dangerous. GHK-Cu appears to solve a copper-delivery problem that evolution had already been solving in human plasma for a very long time.
The translation from laboratory curiosity to practical application didn't happen quickly. Throughout the 1970s and 1980s, Pickart continued publishing on GHK-Cu in academic contexts, describing its effects on wound healing in animal models and its apparent role in stimulating fibroblast activity. The data were accumulating, but the commercial and regulatory machinery to do something with them was slow to engage. Part of the difficulty was that GHK-Cu didn't fit cleanly into existing pharmaceutical categories. It wasn't a hormone. It wasn't a classic anti-inflammatory. It wasn't a growth factor. It was a signaling tripeptide that seemed to do several things at once, which made it difficult to position and even more difficult to study under the frameworks that clinical drug development required.
The Procyte Corporation changed that, at least temporarily. In the late 1980s and through the 1990s, Procyte — a company Pickart was involved in founding — acquired patents on GHK-Cu formulations and began exploring applications in wound healing and skin care. The wound-healing angle was clinically significant: chronic wounds, diabetic ulcers, and slow-healing surgical sites represent an enormous burden of medical care, and any compound that could accelerate tissue repair had commercial value. Procyte developed a product called Iamin Gel, a GHK-Cu formulation for wound healing that received FDA clearance in the early 1990s. It was a genuine regulatory milestone — a copper peptide compound moving through the clinical pathway and earning approval for use in wound care.
Iamin Gel was eventually withdrawn from the market, not for safety reasons but for commercial and strategic ones — a story common enough in the pharmaceutical industry that it barely warrants elaboration. The product didn't fail. The company shifted. But the withdrawal had a subtle effect on the research trajectory: GHK-Cu lost a commercial champion at a moment when it might have attracted the sustained investment needed for broader clinical development. The compound moved, in subsequent decades, more into the territory of topical skincare than pharmaceutical wound care.
The cosmetic industry proved more receptive than the pharmaceutical industry to what GHK-Cu offered. The compound's effects on collagen and elastin synthesis, skin thickness, and photoaging markers made it commercially appealing for anti-aging skincare formulations. Pickart himself went on to found Skin Biology, a company that produced copper peptide skincare products and maintained a substantial scientific publishing program. Companies including NeoStrata incorporated GHK-Cu into their formulations. The cosmetic research arc — studies on skin density improvements, fine line reduction, topical delivery — expanded through the 1990s and 2000s in ways that the pharmaceutical wound-healing arc did not.
Meanwhile, separate research programs were developing in Russia and China in ways that Western literature often underestimates. Soviet-era and post-Soviet Russian biochemistry had a distinct tradition of studying peptide signaling molecules, partly because of theoretical interest in regulatory peptides as a class and partly because the funding and regulatory environments created different research priorities. Russian dermatology and tissue repair literature accumulated studies on GHK-Cu and related copper peptides that parallel, sometimes predate, and sometimes exceed the Western literature in scope. The same compound Pickart had identified in American plasma was being studied in Siberian wound care clinics and Moscow dermatology departments — often with different methodologies, different endpoints, and different levels of rigor, but pointing consistently at the same biological territory.
The Chinese research arc developed somewhat later but became substantial by the 2000s. Chinese academic journals published studies on GHK-Cu in contexts ranging from skin photoaging to wound repair to potential neuroprotective effects. These studies suffer from some of the same limitations as the Russian literature — small sample sizes, variable methodology, limited international replication — but they represent a global recognition that this compound, first isolated in a California lab in the early 1970s, has biological significance that exceeds what Western pharmaceutical development has fully absorbed.
The gene expression findings are what made the twentieth-century research feel newly relevant in the twenty-first. Early research identified a few downstream effects of GHK-Cu — collagen synthesis, wound healing, fibroblast activation. Later research, using the gene array technologies that became available in the 2000s, found something considerably more striking: GHK-Cu appeared to influence the expression of hundreds, and potentially thousands, of human genes. Many of these genes were associated with aging phenotypes — inflammation markers, oxidative stress pathways, DNA repair mechanisms. Some were associated with processes that go wrong in cancer. The compound wasn't doing one thing or five things. It was interacting with the cellular machinery at a level that spoke to its origin: it had been present in human plasma, in high concentration, for the entire period when cells were doing their best work.
That's the implication worth ending on. GHK-Cu wasn't engineered by a pharmaceutical company working toward a target. It was found — in the blood of twenty-year-olds, at concentrations that the body apparently finds optimal for whatever it was using GHK-Cu to do. Its decline with age tracked the biology of aging: not perfectly, not definitively, but consistently enough over five decades of research to suggest that the relationship is meaningful. When biology hides therapeutic clues in plain sight, it usually does so by embedding them in processes that were working so well we never thought to ask why. GHK-Cu was in the plasma all along. We just took until 1973 to notice it, and considerably longer to begin understanding what it was doing there.
Frequently asked